Clinical Trials in Spain / NCT02494986
Active, not recruiting
Phase 2
A Roll-over Study With Rilpivirine for Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Who Participated in Rilpivirine Pediatric Studies
NCT02494986 · tracked via the Priya Life Science Spain tracker
Condition(s) studied
Human Immunodeficiency Virus Type 1
Investigational drug(s) / intervention(s)
Rilpivirine: Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or a weight-adjusted dose, in combination with an investigator selected background regimen consisting of other ARVs.
Study summary
The purpose of this study is to provide continued access to rilpivirine (RPV) for participants who were treated with RPV in a clinical development pediatric study with rilpivirine and who, at the time of roll-over, experience and are expected to continue experiencing clinical benefit from RPV treatment.
Eligibility
Inclusion Criteria:
* Participants (or their legally acceptable representative) must sign an Informed Consent Form (ICF) indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older)
* Participants must be human immunodeficiency virus type 1 (HIV-1) infected and must have previously been treated with rilpivirine (RPV) 25 mg qd (or weight-adjusted dose) in a clinical development pediatric study and completed the protocol-defined treatment period
* Participants must benefit from treatment with RPV, according to the efficacy and safety criteria as set out in the protocol of the pediatric study with RPV the participant was participating in prior to this rollover study, and must be expected to continue to benefit from this treatment in the opinion of the investigator
* Participants must be able and willing to comply with the current protocol requirements
* Participants' general medical condition, in the opinion of the investigator, does not interfere with participation in this study
Exclusion Criteria:
* Participants using disallowed concomitant treatment
* Pregnant participants
* Female participants of childbearing potential and non-vasectomized heterosexually active male participants not willing to continue practicing birth control methods during the study and for greater than or equal to (≥)1 month after the end of the study (or after last intake of RPV)
* Participants who were withdrawn from a pediatric study with RPV that they were participating in prior to this rollover study, based on any of the mandatory withdrawal criteria
Primary outcome measure(s)
- Number of participants with adverse events (AEs) related to rilpivirine (RPV) — Up to 32 Days from the last dose administered (Approximately 16 years)
Evaluation of long term safety of the treatment with RPV with a background regimen. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. - Number of Participants with AEs Leading to Discontinuation — Up to 32 Days from the last dose administered (Approximately 16 years)
Number of participants with AEs leading to discontinuation will be reported. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product. - Number of Participants with Serious Adverse Events (SAEs) — Up to 32 Days from the last dose administered (Approximately 16 years)
Number of participants with SAEs will be reported. An SAE is any adverse event (AE) that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participant and/or may require medical or surgical intervention to prevent one of the outcomes listed above. - Number of Participants with Pregnancies — Up to 32 Days from the last dose of administered (Approximately 16 years)
Number of participants with pregnancies will be reported. - Number or Participants with Grade 3/4 Rash Regardless of Causality — Up to 32 Days from the last dose administered (Approximately 16 years)
Number of participants with grade 3/4 rash regardless of causality will be reported.
Trial sites (8)
| Facility | City | Region | Status |
|---|---|---|---|
| — | Porto | Portugal | |
| — | Bloemfontein | South Africa | |
| — | Dundee | South Africa | |
| — | Esplugues de Llobregat | Spain | |
| — | Bangkok | Thailand | |
| — | Nonthaburi | Thailand | |
| — | Entebbe | Uganda | |
| — | Kampala | Uganda |
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT02494986 on ClinicalTrials.gov ↗ ← All trials in Spain